View : 9 Download: 0

Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy

Title
Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy
Authors
Cho H.Yoon D.H.Lee J.B.Kim S.-Y.Moon J.H.Do Y.R.Lee J.H.Park Y.Lee H.S.Eom H.S.Shin H.-J.Min C.-K.Kim J.S.Jo J.-C.Kang H.J.Mun Y.-C.Lee W.S.Lee J.-J.Suh C.Kim K.and the Korean Multiple Myeloma Working Party
Ewha Authors
문영철
SCOPUS Author ID
문영철scopus
Issue Date
2017
Journal Title
American Journal of Hematology
ISSN
0361-8609JCR Link
Citation
vol. 92, no. 12, pp. 1280 - 1286
Publisher
Wiley-Liss Inc.
Indexed
SCI; SCIE; SCOPUS WOS scopus
Abstract
The revised International Staging System (R-ISS) has recently been developed to improve the risk stratification of multiple myeloma (MM) patients over the ISS. We assessed the R-ISS in MM patients who were treated with novel agents as a primary therapy and evaluated its discriminative power and ability to reclassify patients from the ISS. A total of 514 newly diagnosed MM patients treated with novel agents including thalidomide, bortezomib, and lenalidomide as a primary therapy were included in this retrospective analysis. With a median follow-up duration of 42.3 months (range, 40.5–44.1), the median overall survival (OS) was 61.0 months. There was a significant difference in median OS (not reached, 60.9, and 50.1 months for stages 1, 2, and 3, respectively, P < 0.001) among the three stages of R-ISS. The C-statistic was significantly greater for R-ISS than for ISS (0.769 vs. 0.696, P < 0.001). The event NRI was −0.08 (95% confidence interval [CI], −0.18–0.01) and the non-event NRI was 0.05 (95% CI, −0.03–0.10), resulting in a total NRI of −0.03 (95% CI, −0.14–0.08, P = 0.602). The R-ISS performs well and has significantly better discriminative power than the ISS in MM patients treated with novel agents as a primary therapy. However, it does not better reclassify patients from the ISS, suggesting that there is still room to improve the staging system. Moreover, new statistical measures for assessing and quantifying the risk prediction of new prognostic models are necessary in future studies. © 2017 Wiley Periodicals, Inc.
DOI
10.1002/ajh.24891
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE